Thromboembolic events in immunomodulatory drug (IMiD)–sparing regimens for patients with newly diagnosed multiple myeloma (NDMM). This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results